Jeremy Abramson, MD on CAR T-Cell Therapy
Kiss 108 FM’s Billy Costa gets a doctor’s perspective of CAR T-cell therapy with Mass General Cancer Center’s clinical director for the Center of Lymphoma, Dr. Jeremy Abramson.
About Jeremy Abramson, MD
Dr. Abramson is Professor of Medicine at Harvard Medical School and Director of the Center for Lymphoma at the Mass General Cancer Center. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School. He completed a residency in Internal Medicine at the Massachusetts General Hospital, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson is board certified in Medical Oncology.
Dr. Abramson's clinical and research interests are in lymphoid malignancies, including all non-Hodgkin lymphomas, Hodgkin lymphoma, and chronic lymphoid leukemias. His research involves the design and conduct of clinical trials of new cancer therapies and immunotherapies in lymphomas. Dr. Abramson is the author of numerous research papers and book chapters on lymphoma, and lectures widely.
Departments, Centers, & Programs:
Clinical Interests:
- Chronic lymphocytic leukemia (CLL)
- Hodgkin's lymphoma (also known as Hodgkin's disease)
- Non-Hodgkin's lymphoma (NHL)
Treats:
- Adult
Locations
Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-724-4000
Fax: 617-726-8330
Medical Education
- MD, Mount Sinai School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Brigham and Women's Hospital
- Fellowship, Dana Farber Cancer Institute
- Fellowship, Massachusetts General Hospital
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Abramson designs and conducts clinical trials of novel therapies and immunotherapies including CAR T-cells for the treatment of non-Hodgkin lymphomas, Hodgkin lymphoma (Hodgkin's disease), and chronic lymphocytic leukemia (CLL).
Publications
-
- Abramson JS, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. The Lancet 2024.
- Haydu and Abramson. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Advances 2024.
- Abramson JS, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023.
- Abramson JS, et al. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Advances 2022.
- Abramson JS, et al. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. Blood Advances 2023.
- Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet 2020.
- Abramson JS, et al. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma. Am Soc Clin Oncol Educ Book 2020.
- Abramson JS, et al. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood 2019.
- Abramson JS, et al. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. Am Soc Clin Oncol Educ Book 2019.
- Abramson JS, et al. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.New England Journal of Medicine 2017.
Excellent visit full of clarity and reassurance I was in the best place possible.
Drs. [redacted] and Abramson are simply the best that MGH has to offer. They are both compassionate, caring, intelligent, and thoughtfully answer all my questions. I do not feel rushed when I meet with them.
Dr. Abramson first treated me for Non Hodgkin's Lymphoma in [redacted]. He is knowledgeable, professional, pleasant and empathetic. Having a possible recurrence 15 years later, I looked only to him for counsel. I am blessed to know him and to be treated by him.
Thank you very much to Dr. Abramson and the team for continuous care.
Dr. Abramson reviewed my lab work, asked pertinent questions about my health and provided a thoughtful and comprehensive plan for the upcoming months. I'm grateful to be cared for by someone so wonderful.
The best!
Everyone was kind, professional and helpful. Dr. Abramson is the best! I feel very fortunate to be treated by him. He's kind, professional, thoughtful, thorough and always explains things in a way that I can understand. Thank you for everything you do for me.
Dr. Abramson and his staff are the most informative, nicest people, and knowledgeable that I've ever dealt with. I am definitely am very blessed to be able to go to him and be under his care. So thank you very much.
The doctor was great. He explained everything, extremely friendly, helpful, and even he was at the beginning very emotional support for what we had to go through. So he's a great guy and a great assistant. They were just awesome people. You can't find this kind of doctor anymore.
Dr Abramson is a special person who is extremely thoughtful and caring. He and his team have provided me with the best care and continued follow up. I couldn't have asked for a better experience every time I go to the Lymphoma Center at MGH.